standard medical treatment-Beijing Tiantan Hospital

Standard medical treatment-Beijing Tiantan Hospital refers to a specific pharmacological regimen used as the control arm in the DREAM-PRIDE clinical trial (NCT04152707) for patients with symptomatic intracranial atherosclerotic disease (ICAD). Developed and studied by Beijing Tiantan Hospital, this regimen consists of dual antiplatelet therapy (DAPT) comprising aspirin (100 mg/day) and either clopidogrel (75 mg/day) or ticagrelor (90 mg twice daily). In this protocol, the DAPT duration is limited to 3 months post-enrollment, followed by aspirin monotherapy for the remainder of the follow-up period. It serves as the standard-of-care comparator to evaluate the efficacy of drug-eluting stent (DES) implantation combined with aggressive medical treatment (which involves a longer 6-month DAPT duration) in preventing recurrent stroke.

Other names

Standard medical treatment (DREAM-PRIDE)